Is OMCL a Buy? What to Consider in 2026
Short answer
The bull case for Omnicell (OMCL) rests on Shift toward recurring software and services: Omnicell is steering its revenue mix away from one-time hardware sales toward recurring subscription, cloud, and Advanced Services revenue, which it tracks through annual recurring revenue (ARR). Revenue (FY2025) is ~$1.185 billion (up ~7%). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. Whether OMCL is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Omnicell, Inc. (NASDAQ: OMCL) is a healthcare-technology company that builds medication-management and pharmacy-automation systems for hospitals, health systems, retail and specialty pharmacies, and other care settings. Its core products include automated dispensing cabinets (the XT and XR series), central-pharmacy robotics, IV compounding automation, and a growing layer of cloud software and services branded around what the company calls the Autonomous Pharmacy. Omnicell earns money from product sales (the hardware and installed systems) and from a rising base of recurring service and subscription revenue, including its Advanced Services and technician-enabled offerings, and it tracks annual recurring revenue (ARR) and product bookings as key operating metrics. The investment picture is a turnaround-and-transition story. After a pandemic-era boom and a subsequent slump in hospital capital spending, Omnicell has been steering its mix toward higher-margin recurring revenue while stabilizing its hardware business. Full-year 2025 revenue was about $1.185 billion, up roughly 7% from 2024, with non-GAAP EBITDA of about $140 million, and the company guided 2026 revenue toward roughly $1.215 billion to $1.255 billion. In the first quarter of 2026 revenue grew about 15% year over year to about $310 million, and the company raised its full-year non-GAAP EPS guidance, signaling improving profitability. The bull case rests on ARR growth, expanding margins, and a large installed base of hospital customers; the bear case reflects reliance on cyclical hospital capital budgets, competition from larger rivals, and a GAAP earnings base that has been depressed relative to the share price.
What's the case for buying OMCL?
1. Shift toward recurring software and services.
Omnicell is steering its revenue mix away from one-time hardware sales toward recurring subscription, cloud, and Advanced Services revenue, which it tracks through annual recurring revenue (ARR). Recurring revenue tends to be higher-margin and more predictable than lumpy capital-equipment sales. Continued growth in ARR and the attach rate of software to installed cabinets is central to the company's margin-expansion story.
2. Large installed base and replacement cycle.
Omnicell has a deep footprint of automated dispensing cabinets and pharmacy systems across US hospitals and health systems, which creates recurring service revenue and upgrade or replacement opportunities as older equipment ages. That installed base is a switching-cost moat because ripping out medication-management infrastructure is disruptive for a hospital. New product cycles and expansion into outpatient, retail, and specialty pharmacy settings widen the addressable market.
3. Recovering hospital capital spending and bookings.
After a slump in hospital capital budgets following the pandemic boom, Omnicell has pointed to stabilizing and recovering product bookings, which are a leading indicator of future revenue. First-quarter 2026 revenue grew about 15% year over year to roughly $310 million, and the company raised its full-year non-GAAP EPS guidance. A sustained recovery in health-system capital spending would support both the hardware and the attached-software businesses.
4. Margin and profitability improvement.
Management has focused on cost discipline and mix shift to lift profitability, with non-GAAP EBITDA of about $140 million in 2025 and a step-up in early 2026 (Q1 2026 non-GAAP EPS of about $0.55 versus about $0.26 a year earlier). The 2026 guidance implied a meaningful increase in non-GAAP EPS toward the roughly $1.80 to $2.00 range. Whether these gains translate into durable GAAP earnings is a key watch item.
What are the risks to OMCL?
Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results.
How is OMCL valued? (as of JULY 2026)
Snapshot for OMCL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025): ~$1.185 billion (up ~7%)
- Non-GAAP EBITDA (FY2025): ~$140 million
- Revenue (Q1 2026): ~$310 million (up ~15% YoY)
- Non-GAAP EPS (Q1 2026): ~$0.55 (vs ~$0.26 a year earlier)
- FY2026 Revenue Guidance: ~$1.215-1.255 billion
- FY2026 Non-GAAP EPS Guidance: ~$1.80-2.00
- Market Capitalization: ~$1.96 billion (July 2026)
- Share Price / 52-Week Range: ~$43, range ~$26.85-$55.00
Omnicell trades around $43 per share for a market capitalization near $1.96 billion as of July 2026, with a wide 52-week range that reflects how sensitive the stock is to bookings and margin trends. The trailing GAAP P/E has been very high (around 97) because GAAP earnings have been depressed, while normalized or forward multiples on non-GAAP EPS are far lower (Morningstar cited a normalized P/E near 22). That gap between GAAP and non-GAAP earnings is central to how different investors value the name.
How do you decide if OMCL is a buy?
Rather than asking whether OMCL is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold OMCL indirectly through an index or sector ETF before adding more.
For the full picture, see the OMCL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about OMCL against your real portfolio and see your actual exposure before deciding.
The bottom line on OMCL
The bottom line: Omnicell's story right now is Shift toward recurring software and services, with revenue (fy2025) at ~$1.185 billion (up ~7%). If you believe that narrative continues, the call is about sizing OMCL sensibly and checking overlap with what you own; if you doubt it (the risk: omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around OMCL with Walnut
Use Omnicell as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is OMCL a good stock to buy right now?
+
The case for Omnicell right now is Shift toward recurring software and services, with revenue (fy2025) at ~$1.185 billion (up ~7%). If you believe that thesis holds, OMCL is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Omnicell do?
+
Omnicell, Inc.
What are the main risks of OMCL?
+
Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results.
What does Omnicell do?
+
Omnicell is a healthcare-technology company that sells medication-management and pharmacy-automation systems, including automated dispensing cabinets, central-pharmacy robotics, IV compounding automation, and cloud software, to hospitals, health systems, and pharmacies. It earns revenue from both hardware sales and a growing base of recurring service and subscription contracts.
Is Omnicell profitable?
+
Omnicell generated about $140 million of non-GAAP EBITDA on roughly $1.185 billion of revenue in 2025, and non-GAAP EPS rose sharply in early 2026. Its GAAP earnings, however, have been thin at times, which is why its trailing GAAP P/E has looked very high relative to non-GAAP or normalized measures.
How do I buy OMCL stock?
+
OMCL trades on the Nasdaq, so you can buy whole or fractional shares through any major US broker. Some investors also gain exposure indirectly through healthcare or medical-technology ETFs that hold Omnicell, or by including it as one position in a diversified basket.
Does Omnicell pay a dividend?
+
Omnicell has historically not paid a regular cash dividend, instead reinvesting in its business and, at times, repurchasing shares. Investors looking at OMCL are generally focused on revenue growth, margin expansion, and recurring-revenue trends rather than dividend income.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell OMCL; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.